Plans for a $453.3 million high volume plant and research center were unveiled during an industry forum this week in Republic of Korea.
Celltrion Healthcare has unveiled plans to build a $453.3 million biopharmaceutical plant and research center near its base of operations in Incheon, Republic of Korea. The company said the buildout is supported by rapidly increasing biopharmaceutical demand across the globe.
The biosimilar developer aims to build a 60,000-liter biopharmaceutical plant for diverse types of production needs and also a research center employing 2000 professional biodevelopment personnel for high-level activities related to expanding the company’s pipeline of medicines, including biosimilars, according to a report in the Korea Biomedical Review. The plans were announced during a biopharmaceutical industry forum this week in Korea.
Celltrion aims to complete the research center and the factory by July 2022 and May 2023, respectively, with the factory starting operations by June 2024. The additional plant will give Celltrion a total production capacity of 250,000 liters annually, up from 190,000 at its 2 existing plants.
Eight 7500-liter incubators will shorten the time between manufacture of drug batches, the company said. A fourth plant also is in the planning stages, although further details were not provided, according to the press report.
In August, Samsung Biologics announced plans for $2 billion in spending on what it called the world's largest factory and biopharmaceutical production center, also in Incheon. The company aims to begin production at the site by the second half of 2022.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.